Survival Analysis for Junior Researchers (SAfJR) 2023
SAfJR is an event that is aimed at career-young statisticians with an interest in survival analysis and related research areas. The conference offers an excellent opportunity for young researchers to present and discuss their work with participants at a similar phase in their careers. Keynote speakers, a tutorial, an awarded poster session and a conference dinner are the aims of the Organizing Committee.
The conference started on Wednesday the 13th of September at 9:00 and concluded on Friday the 15th around 12:00. The first half of Wednesday was dedicated to the short course, while the second half featured contributed talks. A poster session was held on Wednesday evening. The second day included contributed talks, one invited talk and the conference dinner. On the third day there were more contributed talks and another invited talk. Please refer to the preliminary program for details.
This year SAfJR was accompanied by three experts in the field of
Sandra Schmeller is a doctoral candidate in Biostatistics at Ulm University. Her current research interests involve multistate models, especially in the field of stem cell transplanted patients data.
Alexander Stemke is a doctoral candidate in Statistics at Ulm University and employee at Boehringer Ingelheim. His research interests involve Bayesian survival analysis, especially with regards to safety analysis and causal inference. Currently dealing with meta-analytic predictive priors to enhance clinical trials.
Judith Vilsmeier is a doctoral candidate in Biostatistics at Ulm University. Her current research interests involve nonstandard event histories and estimation of complex outcomes in non-Markov multistate models.
Jasmin Rühl is a doctoral candidate in Biostatistics at Augsburg University. Her research addresses inference for causal effect estimates in survival data based on different resampling methods
Jan Feifel is a statistician and data scientist at Merck KGaA. He focuses on machine/statistical learning and time-to-event methods for real-world data across therapeutic areas.
Also, he is contributing to the COMBACTE consortium developing non-standard sampling designs and is curious about causal inference.
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.